Trial Profile
A study of Cannabinoids in autism
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 24 Jan 2018
Price :
$35
*
At a glance
- Drugs Cannabinoids (Primary)
- Indications Autistic disorder
- Focus Adverse reactions
- 24 Jan 2018 New trial record
- 23 Jan 2018 According to a Zelda Therapeutics media release, the company plans to initiate this study in 2018.